Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | NAMPT | P43490 | 10/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL160745 | 0.89 | MAOB (0.51) | MCHR1MAOBNAMPTKEAP1ESR1 | |
| Hydrochloric Acid SCHEMBL30259053 | 0.88 | MAOB (0.50) | MCHR1MAOBNAMPTKEAP1ESR1 | |
| Formic Acid SCHEMBL31105273 | 0.84 | MAOB (0.47) | MCHR1MAOBNAMPTKEAP1ESR1 | |
| SCHEMBL173528 | 0.78 | MAOB (0.52) | MCHR1MAOBNAMPTKEAP1ESR1 | |
| Trifluoroacetic Acid SCHEMBL30258754 | 0.77 | NAMPT (0.41) | MCHR1NAMPTKEAP1ESR1DPP4 | |
| Trifluoroacetic Acid SCHEMBL30258895 | 0.77 | NAMPT (0.41) | NAMPTL3MBTL1 | |
| Hydrochloric Acid SCHEMBL15232009 | 0.77 | MAOB (0.51) | MCHR1MAOBNAMPTKEAP1ESR1 | |
| SCHEMBL24231522 | 0.76 | MCHR1 (0.47) | MCHR1MAOBNAMPTKEAP1MEN1 | |
| SCHEMBL28407576 | 0.75 | MAOB (0.50) | MCHR1MAOBNAMPTKEAP1ESR1 | |
| SCHEMBL29272576 | 0.75 | MCHR1 (0.52) | MCHR1MAOBNAMPTKEAP1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118786117-A | Heterocyclic amides and methods of use thereof | 亚根达医疗公司 | 2024-10-15 | — | — | CN | disclosed |
| US-20230087118-A1 | IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | BIOGEN MA INC. | 2023-03-23 | — | — | US | disclosed |
| CN-114245796-A | Imidazo [1,2-a ] pyridinyl derivatives and their use in the treatment of disease | 比奥根MA公司 | 2022-03-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230087118-A1 | IMIDAZO[1,2-a]PYRIDINYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | IRAK4, IRAK2, IRAK1 | MCHR1 3552/4885MAOB 2564/4885NAMPT 2282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.